Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.
about
PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organizationInsulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptorInhibition of tumorigenicity of the teratoma PC cell line by transfection with antisense cDNA for PC cell-derived growth factor (PCDGF, epithelin/granulin precursor)Gene therapy for carcinoma of the breast: Genetic ablation strategiesSurvivin mediates resistance to antiandrogen therapy in prostate cancerSuppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cellsIntegrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatmentNeuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling.Functional analysis of newly discovered growth control genes: experimental approaches.17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis.The contradictions of the insulin-like growth factor 1 receptor.Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer modelInsulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.Additive regulation of hepatic gene expression by dwarfism and caloric restriction.Constitutive activity of the androgen receptor.The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse.The emergence of resistance to targeted cancer therapeutics.Formononetin induces the mitochondrial apoptosis pathway in prostate cancer cells via downregulation of the IGF-1/IGF-1R signaling pathway.Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells.Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma.Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signalingOverexpression of insulin-like growth factor-1 (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts.Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptorOncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges.Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells.The insulin-like growth factor-I receptor as a target for cancer therapy.Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells.Hormone-refractory prostate cancer in the Lobund-Wistar rat.Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cellsSelective modulation of type 1 insulin-like growth factor receptor signaling and functions by beta1 integrins.Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts.Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interferenceEvidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate CancerThe loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.The inhibitory effects of NKX3.1 on IGF-1R expression and its signalling pathway in human prostatic carcinoma PC3 cells.Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
P2860
Q22011202-464BA70E-7D5E-4481-8AEF-CCED8AD99D51Q24338711-0DE28EDA-1D97-49B1-908D-F958F3CF7879Q24652242-2C58C358-B104-41DE-92E1-86C3818ADAEFQ24797953-20192A0E-AB46-441E-998D-6C84AD2BCF05Q28237159-C31E2105-A402-426F-ABEA-BC7F901D5307Q28265036-B05CD2A4-EEC6-4464-8A1E-76001BC08637Q28477824-FDBFF55E-8893-4410-A760-82E65C738109Q30412002-21ED45F3-DA34-4E25-A9F5-3A6FF32FFBCEQ33716358-F07063EC-FA4E-41B0-A5B0-D3CCA1FC18CEQ33821586-E1DBBFFA-2C90-48B6-B362-F5DBDDDBCB6FQ33918953-57A2859A-6419-48BA-BF70-4CEC626DB010Q33959860-05248CCE-2C47-42B2-939F-727F3D9F7569Q34103628-E64A9498-34E4-463E-8D09-7C4B915D6C33Q34123598-318D8E79-DF02-491C-9E25-DB14E9241BB1Q34445822-DBA31CC8-1493-42C3-BEDB-3FC35082A6F8Q34546580-D5FB62D8-98AC-4515-B158-7A941A557384Q34775572-BDC7976E-AEAC-4D2D-9048-4F70DB34575FQ34806020-60DA17FE-2A88-496F-9D8E-4661A76C205AQ34837015-787D1E9C-E769-4E42-AEB4-3C4BC5292EC5Q35073592-B92FE6CD-C88D-4A1C-9953-1D8DBABDE890Q35074494-CB11902A-0D66-4274-8C97-35EB5A515D7AQ35285518-75644A97-B3B1-4286-A592-8B150BA0B658Q35551142-9049E5E6-3D37-4162-BE65-934EBDFA50A8Q35657424-5438862C-5265-493B-9366-41955C478052Q35786221-5063D9C0-EF80-4156-A1B2-9CD98E076DA8Q35788293-04896F47-C1CE-438D-BEE2-3DB78CF79B59Q35838821-D363532F-1DD1-4166-A6DF-B9E948140FE1Q36160109-AA5A6510-90B6-4F3A-AD6B-163120A72816Q36219706-F5908313-343D-4C3C-BC5D-D27FBD0616A8Q36227223-B80361F1-C961-4835-8E49-814ED5DAF9E3Q36239069-B646CB96-A8D8-4FA4-B80A-C07D6197D20BQ36240238-1D1331F5-4F0F-48DD-B0E4-1B0BA3E1C0DEQ36322254-94D5A7CF-4F4D-41A4-83B8-7C952C0C0175Q36429396-3EC8E244-1B29-4B3F-9DBC-165A218E365FQ36528227-3A2A40F2-E4F6-42EE-823A-60ADD85C533CQ36699939-B27F52A6-D465-4B4C-903F-89F768919C5DQ36959130-F10B3C9B-74DE-475D-A69D-EFD0839A5F46Q37037837-6879FC1F-5889-40DC-A1CB-9706A4CDF8D6Q37230780-233AAE90-93CE-4D10-9082-222F65AD7B76Q37258981-CA0CA998-C5C2-4903-8C2C-9189B6B99977
P2860
Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antisense RNA to the type I in ...... prostate cancer cells in vivo.
@en
Antisense RNA to the type I in ...... prostate cancer cells in vivo.
@nl
type
label
Antisense RNA to the type I in ...... prostate cancer cells in vivo.
@en
Antisense RNA to the type I in ...... prostate cancer cells in vivo.
@nl
prefLabel
Antisense RNA to the type I in ...... prostate cancer cells in vivo.
@en
Antisense RNA to the type I in ...... prostate cancer cells in vivo.
@nl
P2093
P2860
P356
P1476
Antisense RNA to the type I in ...... prostate cancer cells in vivo.
@en
P2093
C L Chernicky
F Rininsland
P Burfeind
P2860
P304
P356
10.1073/PNAS.93.14.7263
P407
P577
1996-07-01T00:00:00Z